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For future understanding of biology, we have
to get to grips with complexity. Most bio-
logical processes are based on complex
networks involving many components.
Because they have been generated by
natural selection, redundancies and add-on
functions abound, and some parts may
only be relevant in specific circumstances.
Occam’s razor rarely applies. So how can
sense be made of this complexity?
First, the components involved in the
process of interest have to be identified. To
do this, functional approaches are best,
especially systematic gene deletions that
eliminate all function, although knockdowns
are also useful. However, both approaches
lack the subtleties that can be revealed by
point mutation. Monitoring gene activities
through transcriptomics or proteomics are
useful, but not all changes in expression
during a process are of interest. Once the kit
of parts has been identified, then their
linkages can be determined through genetic
or physical interactions. The consequent
interactome generates a necessary descrip-
tion but unfortunately not always a better
understanding.
For that, we need to know which parts of
the network are at the heart of the process.
One way is to simplify the network by
eliminating functions whilst still maintaining
the core process, through gene deletion,
gene fusion, changing expression, or altering
modification sites. It is a sort of reverse syn-
thetic biology. Reducing the elements to the
minimum will focus attention on those that
are central to the process, and this should
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100 years ago, a Russian pathologist fed
cholesterol to rabbits and produced athero-
sclerosis, thus indicting cholesterol as the
perpetrator. Subsequent epidemiologic,
genetic, and therapeutic data convicted
cholesterol-carrying low density lipoprotein
(LDL) as the culprit. LDL receptor mutations
that increase LDL cause heart attacks in
children. PCSK9 mutations that raise LDL
receptors and lower LDL from birth reduce
heart attacks in adults. Lowering LDL by
diet or statins reduces heart attacks.
Genetics shows that lifelong reduction of
LDL is more effective than lowering LDL later
in life. Each person has a different threshold
for LDL-induced heart attacks. If we knew
this threshold, we would knowwhom to treat
prophylactically, but how to identify the
threshold? Risk factors—hypertension,
smoking, diabetes, low HDL—lower the
threshold and demand prophylaxis. But
what about middle-aged people with
‘‘average’’ LDL and no risk factors? Com-
mon genetic variants are no help because
their effects are small. We need a noninva-
sive method that detects the earliest stage
of atherosclerosis. Biologists, epidemiolo-
gists, and drug inventors have done their
job. Cardiologists and radiologists, please
accept the challenge.
Thresholds are not unique to LDL.
Susceptibility varies for all quantitative traits.
To individualize thresholds, we need deeper
knowledge of disease mechanisms—a
challenge for all physician-scientists.Inc.Telomeres’ Ringside Seat
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Telomeres punch above their weight. The
study of chromosome ends has produced
decadesof remarkablediscoveries. The telo-
mere sequence of Tetrahymena, TTGGGG,
was first decoded in 1978. Since then, a
cascade of discoveries has linked telomeres
to disease. Early studies in yeast and human
cells laid the foundation for understanding
the pivotal role of telomeres in cell survival.
Following the discovery of telomerase, focus
shifted tounderstandinghowthis remarkable
enzyme synthesizes new telomere repeats.
By examining the consequence of telome-
rase deletion, it became clear that short telo-
meres, not the absence of telomeraseper se,
causes cell death and senescence.Cells that
divide must protect against telomere short-
ening, and so, cancer cells and adult stem
cells alike critically depend on telomerase
to cap telomeres. In humans, telomere syn-
drome is marked by short telomeres that
are associated with bone marrow failure
and pulmonary fibrosis as well as GI, liver,
and other diseases. We are still discovering
how this array of age-related degenerative
diseases manifests in so many different tis-
sues. Telomere biology has led the way in
integrating fundamental discovery and
clinical medicine, and both areas have been
enriched. What are the hints for the future?
There are known unknowns: new genes
affecting telomeres, the mystery of telomere
length equilibrium, and tissue-specific
responses in telomere disease. But the
excitement is, of course, in the unknown
unknowns; the joy of discovery comes
from completely unsuspected findings. It is
thrilling to be ringside as the featherweight
telomere moves up a weight class.
Immune Prowess against Cancer
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In its natural state, our immune system fights
cancer poorly. But there are two threads in
modern biology that can interact to change
that perspective. These are immunotherapy
and gene medicine. Both are old hopes
given new momentum by innovative
research. For immunotherapy to work, im-
mune killer cells need to recognize surface
features of cancer cells, bind tightly, and
activate their killing mechanism. In a minority
of cancers, rare patients have such a
response, some even enjoying a ‘‘sponta-
neous cure’’. But new research efforts are
expanding the successes. One key strain of
research is the discovery of ‘‘Checkpoint
Inhibitors’’, proteins like anti-CTLA4 that
take the brakes off immune cells. Another
is the generation of engineered proteins
that can recognize tumor cell surface
molecules. Genes encoding these engi-
neered binding proteins can be implanted
into the genomes of a patient’s own killer
T cells (a form of gene therapy), directing
the cells to kill the patient’s tumor cells. For
a few cancers, apparent cures are being
recorded with these new methods. But
more research is needed before we find
targets on a majority of tumors and learn
how to design targeting molecules for each
tumor. The public has wondered why, after
so many years of funding cancer research,
we havemade so little progress on the major
killers. That perspective is changing and if
we continue supporting innovative ideas,
major progress can be expected in the next
few decades in making our immune systems
work more effectively for us.Cell 157, March 27, 2014 ª2014 Elsevier Inc. 273
